BL22 Immunotoxin in Treating Patients With Refractory Chronic Lymphocytic Leukemia, Prolymphocytic Leukemia, or Non-Hodgkin's Lymphoma

DISEASE CHARACTERISTICS: * Diagnosis of B-cell leukemia or lymphoma of 1 of the following types: * Chronic lymphocytic leukemia * Failed standard chemotherapy * Prolymphocytic leukemia * Failed standard chemotherapy * Indolent non-Hodgkin's lymphoma, including mantle cell lymphoma * Stage III or IV disease * Failed ≥ 1 prior doxorubicin- or fludarabine-containing standard therapy * CD22-positive disease, as evidenced by 1 of the following: * More than 15% malignant cells react with anti-CD22 by immunohistochemistry * More than 30% malignant cells are CD22-positive by fluorescence-activated cell sorting analysis * More than 400 CD22 sites per malignant cell (average) by radiolabeled anti-CD22 binding * Treatment is medically indicated, as evidenced by any of the following: * Progressive disease-related symptoms * Progressive cytopenias due to marrow involvement * Progressive or painful splenomegaly or adenopathy * Rapidly increasing lymphocytosis * Autoimmune hemolytic anemia or thrombocytopenia * Increased frequency of infections * No neutralizing anti-toxin or anti-mouse immunoglobulin G (IgG) antibodies to BL22 or PE38 * No serum neutralization of \> 75% of the activity of 1 μg/mL of BL22 * No CNS disease requiring treatment * No hairy cell leukemia PATIENT CHARACTERISTICS: Age * 18 and over Performance status * ECOG 0-2 Life expectancy * More than 6 months Hematopoietic * Absolute neutrophil count \> 1,000/mm\^3\* * Platelet count \> 40,000/mm\^3 NOTE: \*Patients with leukemia are eligible regardless of absolute neutrophil count; Grade III-IV pancytopenia or growth factor dependence allowed if due to disease Hepatic * Bilirubin \< 1.5 times upper limit of normal (ULN) * ALT and AST \< 2.5 times ULN Renal * Creatinine ≤ 1.5 mg/dL Pulmonary * FEV1 ≥ 60% of predicted * DLCO ≥ 55% of predicted Other * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception * HIV negative PRIOR CONCURRENT THERAPY: Biologic therapy * Prior bone marrow transplantation allowed * More than 3 weeks since prior biologic therapy, including interferon, denileukin diftitox, or LMB-2 immunotoxin * More than 3 months since prior monoclonal antibody therapy (e.g., rituximab) Chemotherapy * See Disease Characteristics * More than 3 weeks since prior cytotoxic chemotherapy Endocrine therapy * More than 1 week since prior steriods * Less than 5 doses for non-treatment reasons (e.g., allergy prophylaxis) * No evidence of disease response Radiotherapy * More than 3 weeks since prior whole-body electron beam radiotherapy * Radiotherapy within the past 3 weeks allowed provided the volume of bone marrow treated is \< 10% AND the patient has measurable disease located outside the radiation port Surgery * Not specified Other * More than 3 weeks since prior retinoids * More than 3 weeks since other prior systemic therapy for this malignancy